Bullfrog AI Holdings, Inc. (BFRG) 股票分析

公司概述

Bullfrog AI Holdings, Inc. operates as a digital biopharmaceutical entity dedicated to leveraging artificial intelligence and machine learning technologies for the analysis of medical and healthcare datasets within the United States. The company specifically offers bfLEAP, an analytical platform designed to process preclinical data, positioning itself at the intersection of technology and pharmaceutical research. It functions within the Healthcare sector, specifically in the Health Information Services industry, which implies a focus on data management and analytical services rather than direct patient care or product manufacturing. The company currently maintains a market capitalization of $19.18M, generates annual revenue of $116,670, and employs 9 individuals to execute its operational strategy. These valuation and revenue figures indicate that the company is a micro-cap entity with a very small operational footprint, suggesting it is in an early-stage development phase where capital allocation is heavily weighted toward research and platform expansion rather than mature commercial scaling.

财务健康

The company reported revenue of $116,670 over the trailing twelve months, while simultaneously recording a net income of -$6,498,068 and an EBITDA of -$6,592,911. The substantial gap between the minimal revenue and the significant net loss reveals an aggressive cost structure driven by high research and development expenditures or operational burn rates typical of early-stage biopharmaceutical firms. Free cash flow stands at -$3,317,732, which indicates that the company is currently consuming cash reserves to fund its operations and growth initiatives rather than generating liquidity from its business activities. The company holds $2.18M in cash and maintains zero debt, resulting in a debt-to-equity ratio that is effectively N/A due to the absence of debt obligations. Gross margin is recorded at 18.8%, reflecting the cost of goods sold relative to sales, while the operating margin is -5652.4% and profit margin is 0.0%, illustrating severe operational inefficiencies or costs that far exceed revenue generation in the current period. Return on Equity is -183.0% and Return on Assets is -98.6%, metrics that reveal the company is currently destroying shareholder value and utilizing assets inefficiently to generate returns. The current ratio is 3.85, which indicates a strong position regarding short-term liquidity as current assets significantly exceed current liabilities despite the overall negative cash flow.

估值评估

Trailing P/E and forward P/E ratios are both listed as N/A, which implies that the lack of positive earnings makes traditional earnings-based valuation multiples inapplicable and suggests the market is pricing the stock based on future potential rather than current profitability. The price-to-book ratio is 5.56, indicating that the market values the company at a significant premium over its book value, a common characteristic for technology-driven firms where intangible assets like intellectual property and data platforms are not fully reflected on the balance sheet. The price-to-sales ratio is 164.44 and the EV/EBITDA is -1.67, suggesting that alternative valuation metrics highlight the high multiple investors are willing to pay for every dollar of revenue despite the negative earnings multiple. The 52-week high is $2.20 and the 52-week low is $0.42, placing the current trading dynamics within a range of $1.78 in historical volatility. The beta value is -2.29, which is an anomalous negative figure indicating that the stock's price movements have historically moved inversely to the broader market with high volatility, deviating from standard correlation models.

Growth & Income

Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, preventing a direct comparison of growth rates but highlighting that the company is in a pre-growth or transitional stage where historical expansion metrics are not yet established. As the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, meaning the company retains all its earnings and cash flow to reinvest into its AI platform and research activities rather than distributing income to shareholders. The absence of a dividend policy combined with negative free cash flow indicates that the company is prioritizing internal capital deployment for long-term strategic goals over providing current income to investors. Overall, the growth and income profile is characterized by a complete lack of historical growth data and income distribution, reflecting the high-risk, high-potential nature of an early-stage digital biopharmaceutical company that relies entirely on future commercialization for value realization.